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Nanomedicines, such as liposomal formulations, play an important role in cancer therapy. To support 
their development, medical imaging modalities are employed for following the drug delivery. 
Encapsulation of MRI contrast agents, which change their relaxivity upon co-release with the drug, is 
a promising strategy for monitoring both the biodistribution and payload release from a nanocarrier. 
This approach is successfully applied in preclinical settings to image the activation of liposomes 
responsive to heat, pH changes or sonication. Recent advances include combination with different 
treatments and the implementation of chemical exchange saturation transfer imaging to gain 
spectral resolution over different contrast agents. However, this field still faces challenges, such as 
matching the pharmacokinetic profiles of the contrast agents and the liberated drugs.  
Introduction 
Cancer nanomedicine continues to hold great promise for targeted chemotherapy that limits harmful 
side effects while enhancing drug solubility and circulation time [1]. It relies mostly on the use of 
lipid- or polymer-based nano-sized carriers filled with a cytotoxic payload that is delivered and 
released in the tumor [2]. Drugs that are approved as liposomal preparations include for instance 
doxorubicin, paclitaxel and vincrisitine, with numerous others being in advanced phases of clinical 
trials [3].  
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The basic principle behind the tumor-selectivity of nanomedicines is the enhanced permeability and 
retention (EPR) effect, whereby the leaky vasculature and decreased lymphatic drainage result in the 
accumulation of the drug in the tumor. However, the selectivity can be further enhanced through the 
use of active targeting moieties (e.g. folate or antibodies)[4] or control over the site of payload 
release, using endogenous (e.g. pH or enzymes) or exogenous (e.g. light, heat, ultrasound) triggers 
[5].  
In the efforts to capitalize on the promise of triggered drug delivery in nanomedicine, the 
development of medical imaging techniques that enable studying the distribution and drug release in 
vivo is of key importance [6]. Here, Magnetic Resonance Imaging (MRI) is often the modality of 
choice, as it offers high resolution with minimal invasiveness and no radiation burden [7,8].  
Incorporation of MRI contrast agents, usually Gd3+ complexes, into nanomedicines (Figure 1a) 
enables their tracking inside the patient body and confirmation of the localization in the tumors. 
However, it provides no information on the efficiency and location of drug release, which depends on 
many factors. For endogeneous triggers, it is not certain if the lower pH or increased enzymatic 
activity in the heterogeneous tumor environment are pronounced enough to act as triggers. For 
exogeneous stimuli, the attenuation of the signal in the tissue (in case of ultrasound and light) and 
the inefficient heat transfer (in hyperthermia) may affect the dose of the trigger needed for efficient 
cargo release. 
 
Figure 1. Approaches to MRI guided liposomal drug delivery. a) Incorporation of a CA in the bilayer 
allows following of the biodistribution of the drug carrier but does not provide information about 
drug release. b) Loading of the CA inside the carrier enables monitoring the cargo release.  
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In this Opinion, we critically review approaches that are aimed at MR imaging of not only the 
nanocarrier distribution, but also the payload release (Figure 1b). The most commonly used strategy 
is the co-encapsulation of the drug and the contrast agent (CA) inside the lumen of the carrier (for an 
overview of the published systems and their characteristics, see Table 1). MRI CAs usually operate on 
the principle of shortening the relaxation time of surrounding water protons. When they are 
encapsulated in the liposome, their action is impaired due to the limited diffusion of water through 
the lipid bilayer. Once the CA is released, enhanced water exchange leads to an increase of relaxivity 
that can be measured in an MRI scan. The following sections describe the main applications of MRI in 
monitoring the payload release from nanomedicines triggered by heat, ultrasound and low pH, 
followed by a critical discussion and outlook on future directions for the field. 
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a) Abbreviations used: Gd-DTPA-BMA: Gadodiamide, Gd-DTPA: Gadopentetate dimeglumine, Gd-HP-
DO3A: Gadoteridol, Gd-BOPTA: Gadobenate dimeglumine, Fe-SDFO: Fe-succinyl deferoxamine, T1: 
longitudinal relaxation time, T2: transverse relaxation time. 
 
Heat-triggered drug release from thermosensitive liposomes (TSL) 
Local induction of hyperthermia is well established to trigger the targeted release of drugs from 
nano-carriers [35,36]. This approach employs, as a vehicle for drug delivery, thermosensitive 
liposomes, whose membrane becomes permeable at a certain temperature. TSLs are prepared by 
adjusting the phase transition temperature (Tm) of the liposomal membrane to 39 – 42 oC, through 
the incorporation of e.g. DPPC (Dipalmitoylphosphatidylcholine) into the bilayer. The Tm needs to be 
tuned in such a way that the liposomes are sufficiently stable at normal temperature but show 
efficient cargo release upon heating [19]. At temperatures around the Tm , the lipids of the bilayer 
coexist in both the solid gel phase and the liquid-crystalline phase, leading to defects in the 
membrane and increased permeability [35]. These characteristics can be further improved by 
expanding the lipid composition with cholesterol [24], lysolipids [36] or DPPG2 [13,14,16,17].  
Heat treatment does not only trigger the targeted release of drugs from liposomes but is also known 
to enhance the antitumor effect [37], due to enhanced permeability and blood circulation, among 
others. It has to be noted that, in contrast to conventional liposomal drug delivery systems, the 
payload of TSL is generally not delivered in an intracellular but intravascular fashion, before the 
liposome is taken up. The various ways of heat delivery to the target tissue used in in vivo studies 
include immersing body parts in a warm water bath, insertion of heated catheters and the use of IR 
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lasers, microwave irradiation or high intensity focused ultrasound (HIFU).  
MR thermometry is regularly used, in particular for monitoring hyperthermia induced by HIFU, and 
dedicated hybrid systems are already established [38,39]. However, in the conventional setups, MRI 
only provides information about the local temperature, but not about the content release from TSL. 
Therefore, loading the TSL with a paramagnetic CA that is liberated together with the cargo when the 
Tm is reached has been investigated. The underlying concept has already been proven in vivo in the 
early 2000, using either Mn2+ or Gd3+-complexes as CA for T1 weighted imaging [9,12]. In the following 
years, the respective systems have been optimized and analyzed in depth, regarding the release 
kinetics [18], the correlation between CA and drug liberation (Figure 3a-c) [15,20], and the influence 
of the time difference between the liposome application and hyperthermia treatment [11] (Table 1). 
Moreover, the combination of heat-induced release of doxorubicin for tumor treatment and thermal 
ablation has been assessed, showing that the shutdown of vasculature due to ablation treatment 
impairs the effectiveness of drug delivery and therefore should be applied after triggering the drug 
release [23]. Another report addresses the challenge of simultaneous MR thermometry and T1 
imaging for monitoring of CA release by introducing an interleaved scan protocol [25]. Besides 
manganese and gadolinium-based CAs, also an iron-complex was evaluated as a CA and the 
respective advantages and disadvantages were evaluated, as described later in this Opinion. 
Moreover, the various examples of TSL differ in their (phospho-)lipid composition and the 
corresponding Tm of the liposome membrane [16,19]. Some reports also asses the possibility of 
multimodal imaging, employing an 111In-complex integrated in the bilayer of the TSL. In such 
applications, the release of the MRI CA can be observed not only by a change in relaxivity but also by 
the loss of co-localization of the SPECT/CT and MRI signal. The exact distribution of doxorubicin and 
liposomal phospholipids can be analyzed by fluorescence imaging and autoradiography respectively 
[21–23].  
In summary, MR imaging of thermally induced content release became an established method in 
preclinical research and has high chances to enter the clinical stage soon. Recent publications focus 
on the practical execution of the MRI scan. Even though the setups for HIFU treatment under MR 
guidance are available, the simultaneous MR thermometry and analysis of contrast agent release 
remains challenging and is addressed in recent reports [25]. 
 
pLINFU-triggered drug release from sonosensitive liposomes 
As opposed to HIFU, which is used to locally increase the temperature and enable payload release 
from thermosensitive liposomes (see the section on heat-triggered drug release), the triggered 
delivery of the cargo using pulsed low intensity non-focused ultrasound (pLINFU) relies on 
mechanical interaction of the nanocontainer with acoustic waves [40,41]. The use of low energy US 
limits the cytotoxicity related to cavitation effects and heating, and enables the activation of non-
thermosensitive nanocontainers [29]. The usefulness of pLINFU in drug delivery has been 
demonstrated in vitro [42] and in in a pre-clinical setting [43,44]. 
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In a seminal series of publications [28–30], Rizzitelli, Terreno and co-workers evaluated the use of 
MRI to study the pLINFU-induced co-release of doxorubicin and gadoteridol from liposomes in vivo. 
Release of the material resulted in T1 signal increase of 35-40% in the tumor in a mouse model [28]. 
In a follow-up study [29], a hybrid protocol was established, in which contrast-enhanced MRI was 
used to guide the payload release and morphological MRI enabled the monitoring of the therapeutic 
effect. Two key aspects of the system were studied: i) using relaxometry (gadoteridol) and 
spectrofluorimetry (doxorubicin), the co-release of both compounds was confirmed in vitro, thereby 
showing that pLINFU does not only increase the water diffusion through the liposome membrane but 
also enables the drug release; ii) liposomes were found to play a crucial role in the permeabilisation 
of the vascular endothelium by pLINFU, likely acting as acoustic resonators. Finally, the same group 
proposed [30] the use of two sequential pulsed US stimuli: one to trigger the release of the drug and 
the other to increase the tumor vascular permeability (sonoporation) and enable the drug diffusion 
to the stroma, leading to an almost complete tumor regression in a breast cancer mouse model. 
A different strategy for visualizing the payload release from liposomes was presented by Delli 
Castelli, Aime and co-workers (Figure 3d) [31]. It is based on chemical exchange saturation transfer 
(CEST) effect, an emerging MR imaging modality. In CEST [45], the localization of molecules that 
contain labile protons with a specific chemical shift can be visualized, through subsequent selective 
magnetic saturation of those protons, allowing their exchange with the pool of water protons, and 
voxel-by-voxel imaging of the saturation. In paraCEST, lanthanide complexes are used that contain 
water-exchangeable protons with chemical shifts that fall outside the range of typical values and can 
therefore be selectively addressed. When paraCEST agents are loaded into liposomes, the exchange 
of protons with bulk water molecules is limited, which quenches the CEST signal. Payload release, 
triggered by insonation, resulted in increased signal. Additionally, lipoCEST effect could be used in 
parallel to visualize drug delivery, using the chemical shift of the intraliposomal water protons. 
 
pH-triggered drug release from acid sensitive liposomes 
The use of increased acidity of the environment as a trigger for drug release from nanocarriers is 
inspired by two effects. Firstly, the interstitial pH in tumors is known to be lower than in healthy 
tissue [46], enabling selective delivery. Secondly, once the liposomes are taken up into the cell, the 
release can be achieved due to higher acidity in the endosomal/lysosomal system [47]. The 
formulation of pH-responsive liposomes is based on combinations of lipids that undergo phase 
transition under acidic condition, usually based on phosphoethanolamine and anionic amphiphiles 
with basic sites [48].  
The model studies on the release of MRI contrast agent gadodiamide from pH-responsive liposomes 
were described by Løkling et al. in a series of papers focusing on in vitro studies [49] and optimization 
[50,51] of MR properties. Those studies were followed by the report from Torres, Terreno and co-
workers [32], who evaluated different gadolinium-based CAs and studied the co-release of the CA 
and a model fluorescent compound at different pH (Figure 2c). 
A conceptually different approach to pH-triggered theranostics nanomaterials is based on systems in 
which the cytotoxic material, or a precursor thereof, itself exhibits MR properties that enable 
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imaging. Zhang, Zhao and co-workers presented [33] liposomes that nano-encapsulate arsenite-
manganese precipitates, in which As3+ ions are used for therapy and Mn2+ ions enable T1- and T2-
weighted MR imaging. After being taken up into cells, the liposomes release the ions in response to 
acidic environment in endosomes/lysosomes, resulting in an increased T1 signal. At the same time, 
the T2 signal decreases due to the dissolution of precipitates that possess magnetic susceptibility. 
T2-weighted imaging can also be used to study the release of toxic iron ions from iron nanoparticles 
(FeNPs), as shown by Yue, Yu and co-workers [34] for a nanoassembly comprising FeNPs and 
graphene oxide functionalized with folic acid for tumor targeting. Also here, the 
endosomal/lysosomal release of iron was envisioned, followed by Fe-catalyzed formation of reactive 
oxygen species from hydrogen peroxide produced by mitochondria. A slow decrease in T2 signal was 
observed in the tumor region in a mouse model, indicative for toxic cargo release. 
The CEST imaging approach to study drug delivery from liposomes, used in the pLINFU-triggered 
approach (see the section on pLINFU-triggered drug release) has been extended also to pH-
responsive systems (Figure 3d) [31]. The use of phosphoethanolamine-derived lipids enabled the 
cargo delivery at pH<6. Interestingly, the use of two different lanthanides (Eu and Tm), in sono- and 
pH-responsive liposomes respectively, enabled the study of release from both nanosystems in 
parallel. This was possible due to the different chemical shift of water in the metal complexes, which 
facilitates selective addressing of them with the saturation pulse. 
 
Figure 2. Studies on the release of cargo from heat- (a and b) and pH-responsive (c) liposomes. 
Changes in T1 relaxivity (r1) and fluorescence during heating and subsequent cooling of traditional 
temperature sensitive liposomes (TTSL, a) and non-temperature sensitive liposomes (NTSL, b). 
Increased fluorescence indicates the release of doxorubicin, since its dilution leads to dequenching. 
a) The irreversible increase in relaxivity and increase in fluorescence shows the release of the CA and 
doxorubicin. b) The reversible relaxivity increase stems from enhanced water permeability of the 
liposomal bilayer at elevated temperature. No increase in fluorescence is observed during heating, 
indicating that no doxorubicin is released. Addition of a detergent (Triton X) to destroy the liposomes 
leads to an increase in fluorescence, proving that the liposomes stayed intact during the 
hyperthermia treatment.  Panels a and b adapted with permission from ref. [19] Copyright 2010, 
Elsevier. c) Fraction of CA and model compound (carboxyfluorescein) release at different pH from 
pH-sensitive liposomes, calculated by increase in relaxivity (squares) and fluorescence (circles). Panel 




Figure 3. MR and CEST imaging of temperature- (a-c), pLINFU- (d) and pH-triggered (d) release of 
content from liposomes. a) Cross-section of a rat in supine position with two tumors, overlaid with 
∆T1dyn map, which shows the difference between the T1 signal before injection and at the end of 
hyperthermia (H1 and H2 indicate the tumor exposed to heat; NH is the non-heated tumor); b) Linear 
regression of doxorubicin concentration (measured by HPLC) with ∆T1dyn; c) Doxorubicin 
concentration map calculated from (a) using regression from (b), selective release of doxorubicin in 
heated tumor is visible; Panels a-c adapted with permission from ref. [17] Copyright 2016, Elsevier. d) 
T2-weighted and CEST map images of a phantom containing liposomes A (pLINFU-sensitive, loaded 
with Eu-based CEST agent with saturation offset of 18 ppm), liposomes B (pH-sensitive, loaded with 
Tm-based CEST agent with saturation offset of 70 ppm) and a mixture thereof. Selective imaging is 
possible when low pH (upper row) or ultrasound (lower row) is applied. Panel d adapted with 
permission from ref. [31]. Copyright 2014 Springer. 
 
Discussion 
The various reports described in this Opinion support the feasibility of MRI-monitored liposomal drug 
delivery that rely on different stimuli to trigger drug release. Nonetheless, this field is still facing 
various challenges and there are a few essential topics for consideration. First of all, the basis of the 
approach lies in the assumption that the CA and the drug are released simultaneously. This certainly 
has to be proven for each individual case, since it depends on the physicochemical properties of the 
two compounds [29]. These properties should therefore be as similar as possible to guarantee 
simultaneous release. Thus, the choice of the CA has a crucial influence on the imaging outcome. 
Besides the release kinetics, also the distribution and metabolism/excretion should ideally coincide. 
Since these characteristics are different for each compound, there is no ideal CA; instead, depending 
on the co-encapsulated drug, the best combination has to be established. Gadolinium complexes, for 
instance, are normally cleared rapidly from the delivery site and tend to accumulate in the liver and 
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spleen. Conversely, manganese ions are often retained at their point of release owing to their 
interaction with phospholipids [27]. Next to gadolinium and manganese, also the use of iron-based 
contrast agents has been suggested, offering the advantage of higher biocompatibility [26]. However, 
the low T1 relaxivity compared to the other two types of CA restricts the application as it imposes the 
use of very high concentrations of the iron complexes. 
The incorporation of high quantities of CAs into the liposomes is limited by the resulting osmotic 
pressure. In this respect, the use of uncharged gadolinium complexes (such as Gd-HP-DO3A or Gd-
DTPA-BMA) is beneficial, as they can be loaded in a higher concentration resulting in a higher change 
in relaxivity before and after release [16]. However, linear uncharged complexes are known to be less 
stable and hence bear a higher risk to release free Gd3+ ions causing severe side effects [52]. One 
strategy to increase the concentration of the CA in the liposomes is to administer the CA and the 
drug independently in two different liposomes [26]. Besides boosting the relaxivity change, this 
approach opens the possibility to deliver two incompatible compounds, such as an iron-complex as 
CA requiring acidic pH and doxorubicin as cytotoxic agent. However, it gives less control over the 
actual co-release of CA and drug and renders the system less reliable, especially in a complex system 
such as the human body. 
In general, it is not only crucial to confirm the co-release of the drug and the CA, but also to prove 
that the increase in relaxivity in fact stems from the release of the CA. As explained above, the 
relaxivity of the encapsulated CA is relatively low due to limited water exchange. Thus, a higher 
water permeability of the liposomal membrane enhances the relaxation rate without actual release 
of the CA (Figure 4a) [9,12]. This way, for example mild hyperthermia below the Tm increases the 
water permeability and can induce a signal increase, erroneously indicating drug release. In contrast 
to signal enhancement by CA release, the relaxivity change is reversible, which can readily be 
analyzed in in vitro experiments to exclude the false positive result as exemplified in figure 2a-b [19]. 
However, the respective experiments do not provide information about the exact mechanism of CA 
release and do not answer the question if the liposomal carrier stays intact after payload delivery. 
Studies using radiolabelled lipids indicate the accumulation of empty liposomes in liver and spleen 
and thus suggest that their cargo is released via transiently formed pores [22].  
Another point to consider is the chronological setup of the treatment [11]. Especially when external 
triggers, such as heat, are applied to induce cargo release from the liposomes, the initiation of 
release and acquisition of MR signal have to be timed carefully. This is even more important when 
the pharmacokinetic profiles of the CA and the drug after release differ. The combination with other 





Figure 4. Consideration points and outlook for the use of MRI in studying the activation of triggered 
nanomedicines. a) Relaxivity increase can stem from the release of the CA with simultaneous drug 
release or only from increased water exchange due to higher permeability of the bilayer. The latter is 
reversible and does not coincide with cargo release. b) Monitoring of orthogonal payload release 
using various liposomes responsive to different stimuli is possible with CEST imaging due to spectral 
resolution of the distinct chemical shifts of the different CEST contrast agents. c) The incorporation of 
a stimuli-responsive contrast agent into the liposomal bilayer, causing disintegration and cargo 
release from the carrier upon a trigger, allows the unambiguous confirmation that the trigger has 
reached the liposome and is not sensitive to spontaneous cargo release. 
 
Conclusion and Outlook 
With the proof-of-principle studies in place, and numerous in vivo reports emerging, the use of MRI 
to follow the release of drugs from nano-carriers gains momentum and is set to develop into hospital 
practice. While the nanomedicine field has been argued to under-deliver on its enormous promise 
[6], we believe that methods that allow the assessment of the location and efficiency of drug release 
will provide the boost for clinical translation. 
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To achieve this, further development of CAs with various properties, which are as similar to those of 
the active substances used nano-carriers, is required. Currently the model applications rely almost 
exclusively on the use of doxorubicin (see Table 1) as a drug, but numerous other drug preparations 
are being approved for clinical use, which would require different CAs to follow. Considering the 
recent concerns on the accumulation of gadolinium in human tissues after CA-enhanced MRI scans 
[53], which led to legal actions prohibiting the use of most linear gadolinium complexes [54], this 
becomes an important challenge that needs to be met if the use of MRI to follow the distribution and 
activation of nanomedicines is to find a general use in clinics. 
The field would further benefit from the establishment of multifunctional membrane constituents 
that not only bear a contrast enhancing moiety but are also susceptible to a trigger resulting in cargo 
release. This way the imaging of nano-carrier activation would be enabled, conveying a higher 
certainty about accordance of the signal increase with liposome responsiveness (Figure 4c).  
Finally, we also highlight here the possibilities offered by the selective delivery of different drugs 
induced by orthogonal stimuli. Since the T1 and T2 relaxivity measurement offer practically no 
spectral resolution, new MRI modalities are needed for this purpose. The emerging CEST imaging 
(Figure 3d) fulfills this requirement, as it enables the imaging of separate CA independently of each 
other due to their distinct chemical shift (Figure 4b). 
With the increasing understanding of the intricacies of the drug/CA release from nanomedicines, a 
set of guidelines for the field emerges. In this opinion, we aimed at highlighting the opportunities, 
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